Abstract: The invention relates to a method for monitoring the condition of rotor blades for wind turbines. It is therefore the object of the invention to increase the accuracy of the monitoring of the condition of rotor blades of wind turbines and to allow a localization of faults or defects and their exact description. In the method in accordance with the invention, eigenvibrations of a rotor blade occurring globally at the rotor blade and locally guided elastic waves are permanently detected with time and spatial resolution using a sensor network and actuator network attached to the rotor blade or using a network arrangement of ultrasound transducers. In addition, elastic waves which are guided periodically at predefinable time intervals and which are respectively emitted by an actuator or ultrasound transducer and detected by sensors or ultrasound transducers are in so doing inspected for variations of the emitted waves.

Abstract: The invention relates to a method for monitoring the condition of rotor blades for wind turbines. It is therefore the object of the invention to increase the accuracy of the monitoring of the condition of rotor blades of wind turbines and to allow a localization of faults or defects and their exact description. In the method in accordance with the invention, eigenvibrations of a rotor blade occurring globally at the rotor blade and locally guided elastic waves are permanently detected with time and spatial resolution using a sensor network and actuator network attached to the rotor blade or using a network arrangement of ultrasound transducers. In addition, elastic waves which are guided periodically at predefinable time intervals and which are respectively emitted by an actuator or ultrasound transducer and detected by sensors or ultrasound transducers are in so doing inspected for variations of the emitted waves.

Abstract: The invention relates to a process for the determination of small substance quantities of medicines, of endogenous or other chemical compounds in biological material, characterized by either binding the compound to be determined and its deuterated analog to an antibody present in excess, which antibody is coupled to a stationary phase of a polymeric material, and separating the two compounds from the antibody and measuring by mass spectrometry the proportion of deuterated compound/not deuterated compound or, respectively, cross-reacting compound; or, in case a suitable deuterated or cross-reacting compound is not available, utilizing as the internal standard also a chemically similar compound which, however, is added after the antibody-mediated extraction, and inserting a separating process before mass spectrometry.

Abstract: Novel, multiple-tritiated steroid-20,17-spirolactones of general Formula I ##STR1## wherein --A--B-- is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or ##STR2## and --C--D-- is ##STR3## R is hydrogen or tritium and n is 0 or 1,are usable as tracer materials for the detection of mineralocorticoid receptors.

Abstract: Compounds of general Formula I labeled with .sup.121 I, .sup.122 I, .sup.123 I, .sup.124 I, .sup.125 I, .sup.131 I and .sup.132 I isotopes ##STR1## wherein R.sup.6 is a C.sub.1-6 aliphatic hydrocarbon residue andC.sub.2 -C.sub.3 C.sub.9 -C.sub.10 is a single or a double bond, as well as their acid addition salts,are useful as diagnostic media, e.g., in imaging dopamine and other receptors.

Abstract: An aqueous crystalline suspension of a 17-tertiary steroid glycoester contains a compound of Formula I ##STR1## wherein X is two hydrogen atoms or an oxygen atom,Y is two hydrogen atoms or a methylene group,R.sup.1 is hydrogen or methyl,Z is hydroxy or --O--CO--R.sup.2R.sup.2 is methyl or phenyl, and ##STR2## in the following fractions: 0-30% by weight of a particle size of 3-15 .mu.m,40-90% by weight of a particle size of 15-60 .mu.m, and20-60% by weight of a particle size of 30-100 .mu.m.Upon a one-time intramuscular injection of 30-75 mg of steroid glycoester as an aqueous crystalline suspension, a steroid level is achieved in the plasma which, over a period of 4 weeks, is adequately high and shows a uniform course.

Abstract: Glycoesters of estradiol (E.sub.2) and of estriol (E.sub.3) of Formula I(E.sub.2,3)--O--CO--CH.sub.2 --Z (I)whereinZ is hydroxy or the group --O--CO--R whereinR is methyl or phenyl,provide a uniform and enduring estrogen level especially when used in the form of an aqueous crystalline suspension.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydroxy-C.sub.2-8 -alkyl containing 1-5 OH-groups;R.sup.2 is hydrogen, C.sub.1-4 -alkyl or R.sup.1 ;R.sup.3 and R.sup.4 can be identical or different, and each independently is hydrogen or C.sub.1-4 -alkyl; andX is straight chain or branched C.sub.2-12 alkylene interrupted by sulfur or selenium atoms, and, optionally, additionally interrupted by oxygen atoms, by a di(C.sub.1-4 -alkyl)silyl group or a tetra(C.sub.1-4 -alkyl)disiloxane group;are very useful as X-ray contrast media opaque agents, which can be employed even in lymphography.

Abstract: A process for preparing an 11-keto steroid consists essentially of heating the corresponding 9.alpha.-halo-11.beta.-hydroxy steroid, to 180.degree.-350.degree. C. in an inert, aprotic, high-boiling solvent.

Abstract: A process for preparing a .DELTA..sup.9(11) - and/or .DELTA..sup.16 -unsaturated steroid comprises heating the corresponding steroid of the pregnane series substituted by 9.alpha.-chloro- and/or 16.alpha.-chloro- or 17.alpha.-acyloxy, in an inert, aprotic high-boiling solvent at 180.degree.-350.degree. C.

Abstract: Organic radiohalogen compounds are prepared by heating in a non-aqueous liquid phase a mixture of a radioinactive organic halogen compound and an alkali metal halogenide or alkaline earth halogenide wherein the halogenide is F-18, Cl-38, Br-82 or I-123, -125, -131 or -132.